Literature DB >> 28579221

STAT3 in cancer: A double edged sword.

Lidia Avalle1, Annalisa Camporeale1, Andrea Camperi1, Valeria Poli2.   

Abstract

The transcription factor signal transducer and activator of transcription (STAT) 3 is activated downstream of cytokines, growth factors and oncogenes to mediate their functions under both physiological and pathological conditions. In particular, aberrant/unrestrained STAT3 activity is detected in a wide variety of tumors, driving multiple pro-oncogenic functions. For that, STAT3 is widely considered as an oncogene and is the object of intense translational studies. One of the distinctive features of this factor is however, its ability to elicit different and sometimes contrasting effects under different conditions. In particular, STAT3 activities have been shown to be either pro-oncogenic or tumor-suppressive according to the tumor aetiology/mutational landscape, suggesting that the molecular bases underlining its functions are still incompletely understood. Here we discuss some of the properties that may provide the bases to explain STAT3 heterogeneous functions, and in particular how post-translational modifications contribute shaping its sub-cellular localization and activities, the cross talk between these activities and cell metabolic conditions, and finally how its functions can control the behaviour of both tumor and tumor microenvironment cell populations.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Post-translational modifications; STAT3; Tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28579221     DOI: 10.1016/j.cyto.2017.03.018

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  57 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

2.  Deletion of caveolin scaffolding domain alters cancer cell migration.

Authors:  Sunaho Okada; Sadaf A Raja; Jonathan Okerblom; Aayush Boddu; Yousuke Horikawa; Supriyo Ray; Hideshi Okada; Itta Kawamura; Yoshiteru Murofushi; Fiona Murray; Hemal H Patel
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

Review 3.  The role of an anti-diabetic drug metformin in the treatment of endocrine tumors.

Authors:  Shilpa Thakur; Brianna Daley; Joanna Klubo-Gwiezdzinska
Journal:  J Mol Endocrinol       Date:  2019-08       Impact factor: 5.098

4.  STAT3β is a tumor suppressor in acute myeloid leukemia.

Authors:  Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber
Journal:  Blood Adv       Date:  2019-07-09

5.  The expression and the tumor suppressor role of CLDN6 in colon cancer.

Authors:  Huinan Qu; Min Wang; Miaomiao Wang; Yuanyuan Liu; Chengshi Quan
Journal:  Mol Cell Biochem       Date:  2022-06-14       Impact factor: 3.396

6.  STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.

Authors:  Dayson Moreira; Tomasz Adamus; Xingli Zhao; Yu-Lin Su; Zhuoran Zhang; Seok Voon White; Piotr Swiderski; Xin Lu; Ronald A DePinho; Sumanta K Pal; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2018-10-18       Impact factor: 12.531

Review 7.  Effect of the transcription factor YY1 on the development of pancreatic endocrine and exocrine tumors: a narrative review.

Authors:  Qun Chen; Wu-Jun Wang; Yun-Xuan Jia; Hao Yuan; Peng-Fei Wu; Wan-Li Ge; Ling-Dong Meng; Xu-Min Huang; Peng Shen; Tao-Yue Yang; Yi Miao; Jing-Jing Zhang; Kui-Rong Jiang
Journal:  Cell Biosci       Date:  2021-05-13       Impact factor: 7.133

Review 8.  Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.

Authors:  Vikram Shaw; Suyash Srivastava; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2019-10-13       Impact factor: 15.707

Review 9.  Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response.

Authors:  Michelle von Locquenghien; Catalina Rozalén; Toni Celià-Terrassa
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

10.  STAT3 localizes to the ER, acting as a gatekeeper for ER-mitochondrion Ca2+ fluxes and apoptotic responses.

Authors:  Lidia Avalle; Annalisa Camporeale; Giampaolo Morciano; Natascia Caroccia; Elena Ghetti; Valeria Orecchia; Daniele Viavattene; Carlotta Giorgi; Paolo Pinton; Valeria Poli
Journal:  Cell Death Differ       Date:  2018-07-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.